

NATIONAL COLLABORATING CENTRE FOR CANCER (NCC-C)

Non-Hodgkin's Lymphoma (NHL)

8th Guideline Committee (GC) meeting

27th March 2015

Bollin Room, NICE Offices, City Tower, Manchester, M4 1BT

GROUP MEMBERSHIP

GDG Members	
David Linch (DL) (Chair)	Christopher McNamara (CM) (Clinical Lead)
Ian Chau (IC)	Bhuey Sharma (BS)
Kim Linton (KL)	Jennifer Wimperis (JW)
Graham Collins (GC)	Karl Peggs (KP)
Tessa Somerville (TS)	Morag Day (MD)
Katharine Robinson (KR)	Gillian Howard-Jones (GHJ)
Andrew Jack (AJ)	Peter Hoskin (PH)
NCC-C staff	
Lianne Gwillim (LG)	Matthew Prettyjohns (MP)
John Graham (JG)	Nathan Bromham (NB)
Debbie Fitzsimmons (DF)	Kateryna Onishchenko (KO)
NICE staff	
Thomas Feist (TF)	Trudie Willingham (TW)
Apologies	
Jacqueline Green (JGr)	Laura Bunting (LB)
Sabine Berendse (SB)	Katie Perryman Ford (KPF)
Andrew Champion (AC)	

REPORTS OF DISCUSSION AT THE MEETING

1. Introductions

DL welcomed everyone and thanked them for attending the 8th meeting of the NHL Guideline Committee.

Apologies for absence were received from, Jackie Green (JGr), Laura Bunting (LB), Andrew Champion (AC) and Katie Perryman Ford (KPF).

A welcome was given to:

- Matthew Prettyjohns (MP), Senior Health Economist from the NCCC
- Nathan Bromham (NB), Senior Researcher from the NCCC, attending on behalf of LB.
- Thomas Feist (TF), Clinical Guidelines Coordinator from NICE, who was attending the meeting on behalf KPF.
- Trudie Willingham, also a Clinical Guidelines Coordinator from NICE who was attending as an observer.

2. Declarations of interest

The following declarations of interest were made prior the meeting:

- TS received travel expenses from Haemo-Onv for volunteer work on the ward. This interest was categorised as personal pecuniary, non-specific. TS can declare and participate in discussions on all topics expenses were not beyond reasonable amounts
- GHJ received travel expenses from Brighton team and Janssen to talk about the new follow up service at Southampton. This interest was categorised as personal pecuniary, specific. GHJ can declare and participate in discussions on all topics expenses were not beyond reasonable amounts.
- KL is a member of the Gilead Oncology faculty to provide haematology-oncology expert and speaker training and slide resource on Idelalisib. This interest was categorised as personal non-pecuniary. KL can declare and participate in discussions on all topics as Idelalisib is being investigated by TA's and therefore will not be investigated by the guideline.
- IC received honorarium from Bayer for attending an advisory board meeting on anti-coagulates. This interest was categorised as personal pecuniary, non-specific. IC can declare and participate in discussions on all topics as anti-coagulates drugs are not being investigated by the guideline.
- GC received honorarium from Takeda for attending an advisory board meeting on Brentuximab Vedotin in Hodgkins Lymphoma and Aplastic large cell lymphoma. This interest was categorised as personal pecuniary, specific. GC can declare and participate in discussions on all topics as Hodgkins Lymphoma and Aplastic large cell lymphoma is not the focus of the guideline.
- GC received honorarium from Takeda for attending an advisory board meeting on Brentuximab Vedotin in Hodgkins Lymphoma and Aplastic large cell lymphoma. This interest was categorised as personal pecuniary, specific. GC can declare and participate in discussions on all topics as Hodgkins Lymphoma and aplastic large cell lymphoma is not the focus of the guideline.
- GC received honorarium from Gilead for a talk at an idelalisib launch event in Birmingham. The talk was focused on the treatment of follicular lymphoma which has become resistant to alkylation agents and rituximab. This interest was categorised as personal pecuniary, specific. GC can declare and participate in discussions on all topics as the treatment of follicular lymphoma which has become resistant to alkylation agents and rituximab is not the focus of the guideline.

The GC were reminded that if they take on any new interests, these must be declared to the NCC-C as soon as they happen so that the necessary action can be taken.

3. Discussions

A presentation was made to the GC on the health economic pathway and model structure for topic H.

The GC discussed the cancer patient experience survey and the recommendations for topic A.

The GC discussed the clinical evidence and agreed the recommendations for topics G & K1.

4. Date and venue of next meeting

DL thanked the GC for their input to the meeting and reminded them that the next meeting would be on **Wednesday 3rd June 2015, at the NCCC Offices, Park House, Greyfriars Road, Cardiff, CF10 3AF.**